{"context":{"query":">>uniprot>>reactome","source_dataset":"uniprot","target_dataset":"reactome"},"stats":{"queried":6,"total":228,"mapped":6},"pagination":{"has_next":false},"schema":"id|name|tax_id|is_disease_pathway","mappings":[{"input":"P00533","source":"P00533|Epidermal growth factor receptor","targets":["R-HSA-1227986|Signaling by ERBB2|9606|false","R-HSA-1236382|Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants|9606|true","R-HSA-1236394|Signaling by ERBB4|9606|false","R-HSA-1250196|SHC1 events in ERBB2 signaling|9606|false","R-HSA-1251932|PLCG1 events in ERBB2 signaling|9606|false","R-HSA-1257604|PIP3 activates AKT signaling|9606|false","R-HSA-177929|Signaling by EGFR|9606|false","R-HSA-179812|GRB2 events in EGFR signaling|9606|false","R-HSA-180292|GAB1 signalosome|9606|false","R-HSA-180336|SHC1 events in EGFR signaling|9606|false","R-HSA-182971|EGFR downregulation|9606|false","R-HSA-1963640|GRB2 events in ERBB2 signaling|9606|false","R-HSA-1963642|PI3K events in ERBB2 signaling|9606|false","R-HSA-212718|EGFR interacts with phospholipase C-gamma|9606|false","R-HSA-2179392|EGFR Transactivation by Gastrin|9606|false","R-HSA-2219530|Constitutive Signaling by Aberrant PI3K in Cancer|9606|true","R-HSA-445144|Signal transduction by L1|9606|false","R-HSA-5637810|Constitutive Signaling by EGFRvIII|9606|true","R-HSA-5638303|Inhibition of Signaling by Overexpressed EGFR|9606|true","R-HSA-5673001|RAF/MAP kinase cascade|9606|false","R-HSA-6785631|ERBB2 Regulates Cell Motility|9606|false","R-HSA-6811558|PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling|9606|false","R-HSA-8847993|ERBB2 Activates PTK6 Signaling|9606|false","R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis|9606|false","R-HSA-8856828|Clathrin-mediated endocytosis|9606|false","R-HSA-8857538|PTK6 promotes HIF1A stabilization|9606|false","R-HSA-8863795|Downregulation of ERBB2 signaling|9606|false","R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors|9606|false","R-HSA-9009391|Extra-nuclear estrogen signaling|9606|false","R-HSA-9013507|NOTCH3 Activation and Transmission of Signal to the Nucleus|9606|false","R-HSA-9609690|HCMV Early Events|9606|true","R-HSA-9634638|Estrogen-dependent nuclear events downstream of ESR-membrane signaling|9606|false","R-HSA-9664565|Signaling by ERBB2 KD Mutants|9606|true","R-HSA-9665348|Signaling by ERBB2 ECD mutants|9606|true","R-HSA-9665686|Signaling by ERBB2 TMD/JMD mutants|9606|true","R-HSA-9820960|Respiratory syncytial virus (RSV) attachment and entry|9606|true","R-HSA-9927432|Developmental Lineage of Mammary Gland Myoepithelial Cells|9606|false"]},{"input":"P04626","source":"P04626|Receptor tyrosine-protein kinase erbB-2","targets":["R-HSA-1227986|Signaling by ERBB2|9606|false","R-HSA-1250196|SHC1 events in ERBB2 signaling|9606|false","R-HSA-1251932|PLCG1 events in ERBB2 signaling|9606|false","R-HSA-1257604|PIP3 activates AKT signaling|9606|false","R-HSA-1306955|GRB7 events in ERBB2 signaling|9606|false","R-HSA-1358803|Downregulation of ERBB2:ERBB3 signaling|9606|false","R-HSA-1963640|GRB2 events in ERBB2 signaling|9606|false","R-HSA-1963642|PI3K events in ERBB2 signaling|9606|false","R-HSA-2219530|Constitutive Signaling by Aberrant PI3K in Cancer|9606|true","R-HSA-416572|Sema4D induced cell migration and growth-cone collapse|9606|false","R-HSA-5673001|RAF/MAP kinase cascade|9606|false","R-HSA-6785631|ERBB2 Regulates Cell Motility|9606|false","R-HSA-6811558|PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling|9606|false","R-HSA-8847993|ERBB2 Activates PTK6 Signaling|9606|false","R-HSA-8863795|Downregulation of ERBB2 signaling|9606|false","R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors|9606|false","R-HSA-9634285|Constitutive Signaling by Overexpressed ERBB2|9606|true","R-HSA-9652282|Drug-mediated inhibition of ERBB2 signaling|9606|false","R-HSA-9664565|Signaling by ERBB2 KD Mutants|9606|true","R-HSA-9665233|Resistance of ERBB2 KD mutants to trastuzumab|9606|true","R-HSA-9665244|Resistance of ERBB2 KD mutants to sapitinib|9606|true","R-HSA-9665245|Resistance of ERBB2 KD mutants to tesevatinib|9606|true","R-HSA-9665246|Resistance of ERBB2 KD mutants to neratinib|9606|true","R-HSA-9665247|Resistance of ERBB2 KD mutants to osimertinib|9606|true","R-HSA-9665249|Resistance of ERBB2 KD mutants to afatinib|9606|true","R-HSA-9665250|Resistance of ERBB2 KD mutants to AEE788|9606|true","R-HSA-9665251|Resistance of ERBB2 KD mutants to lapatinib|9606|true","R-HSA-9665348|Signaling by ERBB2 ECD mutants|9606|true","R-HSA-9665686|Signaling by ERBB2 TMD/JMD mutants|9606|true","R-HSA-9665737|Drug resistance in ERBB2 TMD/JMD mutants|9606|true","R-HSA-9927418|Developmental Lineage of Mammary Gland Luminal Epithelial Cells|9606|false","R-HSA-9927432|Developmental Lineage of Mammary Gland Myoepithelial Cells|9606|false","R-HSA-9938206|Developmental Lineage of Mammary Stem Cells|9606|false"]},{"input":"Q9UM73","source":"Q9UM73|ALK tyrosine kinase receptor","targets":["R-HSA-201556|Signaling by ALK|9606|false","R-HSA-9700645|ALK mutants bind TKIs|9606|true","R-HSA-9717264|ASP-3026-resistant ALK mutants|9606|true","R-HSA-9717301|NVP-TAE684-resistant ALK mutants|9606|true","R-HSA-9717316|alectinib-resistant ALK mutants|9606|true","R-HSA-9717319|brigatinib-resistant ALK mutants|9606|true","R-HSA-9717323|ceritinib-resistant ALK mutants|9606|true","R-HSA-9717326|crizotinib-resistant ALK mutants|9606|true","R-HSA-9717329|lorlatinib-resistant ALK mutants|9606|true","R-HSA-9725370|Signaling by ALK fusions and activated point mutants|9606|true","R-HSA-9851151|MDK and PTN in ALK signaling|9606|false"]},{"input":"P15056","source":"P15056|Serine/threonine-protein kinase B-raf","targets":["R-HSA-1295596|Spry regulation of FGF signaling|9606|false","R-HSA-170968|Frs2-mediated activation|9606|false","R-HSA-170984|ARMS-mediated activation|9606|false","R-HSA-187706|Signalling to p38 via RIT and RIN|9606|false","R-HSA-5673000|RAF activation|9606|false","R-HSA-5674135|MAP2K and MAPK activation|9606|false","R-HSA-5674499|Negative feedback regulation of MAPK pathway|9606|false","R-HSA-5675221|Negative regulation of MAPK pathway|9606|false","R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants|9606|true","R-HSA-6802948|Signaling by high-kinase activity BRAF mutants|9606|true","R-HSA-6802952|Signaling by BRAF and RAF1 fusions|9606|true","R-HSA-6802955|Paradoxical activation of RAF signaling by kinase inactive BRAF|9606|true","R-HSA-9649948|Signaling downstream of RAS mutants|9606|true","R-HSA-9656223|Signaling by RAF1 mutants|9606|true","R-HSA-9726840|SHOC2 M1731 mutant abolishes MRAS complex function|9606|true","R-HSA-9726842|Gain-of-function MRAS complexes activate RAF signaling|9606|true"]},{"input":"P01116","source":"P01116|GTPase KRas","targets":["R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants|9606|true","R-HSA-6802955|Paradoxical activation of RAF signaling by kinase inactive BRAF|9606|true","R-HSA-8951936|RUNX3 regulates p14-ARF|9606|false","R-HSA-9648002|RAS processing|9606|false","R-HSA-9649948|Signaling downstream of RAS mutants|9606|true","R-HSA-9674555|Signaling by CSF3 (G-CSF)|9606|false","R-HSA-9680350|Signaling by CSF1 (M-CSF) in myeloid cells|9606|false","R-HSA-9753510|Signaling by RAS GAP mutants|9606|true","R-HSA-9753512|Signaling by RAS GTPase mutants|9606|true","R-HSA-112412|SOS-mediated signalling|9606|false","R-HSA-1169092|Activation of RAS in B cells|9606|false","R-HSA-1236382|Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants|9606|true","R-HSA-1250196|SHC1 events in ERBB2 signaling|9606|false","R-HSA-1250347|SHC1 events in ERBB4 signaling|9606|false","R-HSA-1433557|Signaling by SCF-KIT|9606|false","R-HSA-167044|Signalling to RAS|9606|false","R-HSA-171007|p38MAPK events|9606|false","R-HSA-179812|GRB2 events in EGFR signaling|9606|false","R-HSA-180336|SHC1 events in EGFR signaling|9606|false","R-HSA-186763|Downstream signal transduction|9606|false","R-HSA-1963640|GRB2 events in ERBB2 signaling|9606|false","R-HSA-210993|Tie2 Signaling|9606|false","R-HSA-2179392|EGFR Transactivation by Gastrin|9606|false","R-HSA-2424491|DAP12 signaling|9606|false","R-HSA-2428933|SHC-related events triggered by IGF1R|9606|false","R-HSA-2871796|FCERI mediated MAPK activation|9606|false","R-HSA-375165|NCAM signaling for neurite out-growth|9606|false","R-HSA-4086398|Ca2+ pathway|9606|false","R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor|9606|false","R-HSA-5218921|VEGFR2 mediated cell proliferation|9606|false","R-HSA-5621575|CD209 (DC-SIGN) signaling|9606|false","R-HSA-5637810|Constitutive Signaling by EGFRvIII|9606|true","R-HSA-5654688|SHC-mediated cascade:FGFR1|9606|false","R-HSA-5654693|FRS-mediated FGFR1 signaling|9606|false","R-HSA-5654699|SHC-mediated cascade:FGFR2|9606|false","R-HSA-5654700|FRS-mediated FGFR2 signaling|9606|false","R-HSA-5654704|SHC-mediated cascade:FGFR3|9606|false","R-HSA-5654706|FRS-mediated FGFR3 signaling|9606|false","R-HSA-5654712|FRS-mediated FGFR4 signaling|9606|false","R-HSA-5654719|SHC-mediated cascade:FGFR4|9606|false","R-HSA-5655253|Signaling by FGFR2 in disease|9606|true","R-HSA-5655291|Signaling by FGFR4 in disease|9606|true","R-HSA-5655302|Signaling by FGFR1 in disease|9606|true","R-HSA-5655332|Signaling by FGFR3 in disease|9606|true","R-HSA-5658442|Regulation of RAS by GAPs|9606|false","R-HSA-5673000|RAF activation|9606|false","R-HSA-5673001|RAF/MAP kinase cascade|9606|false","R-HSA-5674135|MAP2K and MAPK activation|9606|false","R-HSA-5675221|Negative regulation of MAPK pathway|9606|false","R-HSA-6802948|Signaling by high-kinase activity BRAF mutants|9606|true","R-HSA-6802952|Signaling by BRAF and RAF1 fusions|9606|true","R-HSA-6802953|RAS signaling downstream of NF1 loss-of-function variants|9606|true","R-HSA-74751|Insulin receptor signalling cascade|9606|false","R-HSA-8849471|PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases|9606|false","R-HSA-8851805|MET activates RAS signaling|9606|false","R-HSA-9026519|Activated NTRK2 signals through RAS|9606|false","R-HSA-9027284|Erythropoietin activates RAS|9606|false","R-HSA-9028731|Activated NTRK2 signals through FRS2 and FRS3|9606|false","R-HSA-9034864|Activated NTRK3 signals through RAS|9606|false","R-HSA-9607240|FLT3 Signaling|9606|false","R-HSA-9634285|Constitutive Signaling by Overexpressed ERBB2|9606|true","R-HSA-9634635|Estrogen-stimulated signaling through PRKCZ|9606|false","R-HSA-9656223|Signaling by RAF1 mutants|9606|true","R-HSA-9664565|Signaling by ERBB2 KD Mutants|9606|true","R-HSA-9665348|Signaling by ERBB2 ECD mutants|9606|true","R-HSA-9665686|Signaling by ERBB2 TMD/JMD mutants|9606|true","R-HSA-9670439|Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants|9606|true","R-HSA-9673767|Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants|9606|true","R-HSA-9673770|Signaling by PDGFRA extracellular domain mutants|9606|true","R-HSA-9703465|Signaling by FLT3 fusion proteins|9606|true","R-HSA-9703648|Signaling by FLT3 ITD and TKD mutants|9606|true"]},{"input":"P42336","source":"P42336|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform","targets":["R-HSA-109704|PI3K Cascade|9606|false","R-HSA-112399|IRS-mediated signalling|9606|false","R-HSA-114604|GPVI-mediated activation cascade|9606|false","R-HSA-1236382|Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants|9606|true","R-HSA-1250342|PI3K events in ERBB4 signaling|9606|false","R-HSA-1257604|PIP3 activates AKT signaling|9606|false","R-HSA-1433557|Signaling by SCF-KIT|9606|false","R-HSA-1660499|Synthesis of PIPs at the plasma membrane|9606|false","R-HSA-180292|GAB1 signalosome|9606|false","R-HSA-1839117|Signaling by cytosolic FGFR1 fusion mutants|9606|true","R-HSA-186763|Downstream signal transduction|9606|false","R-HSA-1963642|PI3K events in ERBB2 signaling|9606|false","R-HSA-198203|PI3K/AKT activation|9606|false","R-HSA-201556|Signaling by ALK|9606|false","R-HSA-202424|Downstream TCR signaling|9606|false","R-HSA-2029485|Role of phospholipids in phagocytosis|9606|false","R-HSA-210993|Tie2 Signaling|9606|false","R-HSA-2219530|Constitutive Signaling by Aberrant PI3K in Cancer|9606|true","R-HSA-2424491|DAP12 signaling|9606|false","R-HSA-2730905|Role of LAT2/NTAL/LAB on calcium mobilization|9606|false","R-HSA-373753|Nephrin family interactions|9606|false","R-HSA-389357|CD28 dependent PI3K/Akt signaling|9606|false","R-HSA-416476|G alpha (q) signalling events|9606|false","R-HSA-4420097|VEGFA-VEGFR2 Pathway|9606|false","R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling|9606|false","R-HSA-5637810|Constitutive Signaling by EGFRvIII|9606|true","R-HSA-5654689|PI-3K cascade:FGFR1|9606|false","R-HSA-5654695|PI-3K cascade:FGFR2|9606|false","R-HSA-5654710|PI-3K cascade:FGFR3|9606|false","R-HSA-5654720|PI-3K cascade:FGFR4|9606|false","R-HSA-5655253|Signaling by FGFR2 in disease|9606|true","R-HSA-5655291|Signaling by FGFR4 in disease|9606|true","R-HSA-5655302|Signaling by FGFR1 in disease|9606|true","R-HSA-5655332|Signaling by FGFR3 in disease|9606|true","R-HSA-5673001|RAF/MAP kinase cascade|9606|false","R-HSA-6811558|PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling|9606|false","R-HSA-8851907|MET activates PI3K/AKT signaling|9606|false","R-HSA-8853659|RET signaling|9606|false","R-HSA-9009391|Extra-nuclear estrogen signaling|9606|false","R-HSA-9013149|RAC1 GTPase cycle|9606|false","R-HSA-9013404|RAC2 GTPase cycle|9606|false","R-HSA-9027276|Erythropoietin activates Phosphoinositide-3-kinase (PI3K)|9606|false","R-HSA-9028335|Activated NTRK2 signals through PI3K|9606|false","R-HSA-912526|Interleukin receptor SHC signaling|9606|false","R-HSA-912631|Regulation of signaling by CBL|9606|false","R-HSA-9603381|Activated NTRK3 signals through PI3K|9606|false","R-HSA-9607240|FLT3 Signaling|9606|false","R-HSA-9664565|Signaling by ERBB2 KD Mutants|9606|true","R-HSA-9665348|Signaling by ERBB2 ECD mutants|9606|true","R-HSA-9670439|Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants|9606|true","R-HSA-9673767|Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants|9606|true","R-HSA-9673770|Signaling by PDGFRA extracellular domain mutants|9606|true","R-HSA-9680350|Signaling by CSF1 (M-CSF) in myeloid cells|9606|false","R-HSA-9703465|Signaling by FLT3 fusion proteins|9606|true","R-HSA-9703648|Signaling by FLT3 ITD and TKD mutants|9606|true","R-HSA-9725370|Signaling by ALK fusions and activated point mutants|9606|true","R-HSA-9842640|Signaling by LTK in cancer|9606|true","R-HSA-9842663|Signaling by LTK|9606|false","R-HSA-9856530|High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells|9606|false","R-HSA-9927354|Co-stimulation by ICOS|9606|false"]}]}